Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Investigation of ranibizumab for the treatment of persistent diabetic neovascularization as assessed by super wide-field angiography (optos).

Trial Profile

Investigation of ranibizumab for the treatment of persistent diabetic neovascularization as assessed by super wide-field angiography (optos).

Completed
Phase of Trial: Phase I/II

Latest Information Update: 25 Nov 2014

At a glance

  • Drugs Ranibizumab (Primary)
  • Indications Diabetic retinopathy
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 29 May 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 21 Jul 2011 Actual end date (Oct 2010) added as reported by ClinicalTrials.gov.
    • 01 Mar 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top